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Summary
To characterize somatic alterations in colorectal carcinoma (CRC), we conducted genome-scale 
analysis of 276 samples, analyzing exome sequence, DNA copy number, promoter methylation, 
mRNA and microRNA expression. A subset (97) underwent low-depth-of-coverage whole-
genome sequencing. 16% of CRC have hypermutation, three quarters of which have the expected 
high microsatellite instability (MSI), usually with hypermethylation and MLH1 silencing, but one 
quarter has somatic mismatch repair gene mutations. Excluding hypermutated cancers, colon and 
rectum cancers have remarkably similar patterns of genomic alteration. Twenty-four genes are 
significantly mutated. In addition to the expected APC, TP53, SMAD4, PIK3CA and KRAS 
mutations, we found frequent mutations in ARID1A, SOX9, and FAM123B/WTX. Recurrent copy 
number alterations include potentially drug-targetable amplifications of ERBB2 and newly 
discovered amplification of IGF2. Recurrent chromosomal translocations include fusion of NAV2 
and WNT pathway member TCF7L1. Integrative analyses suggest new markers for aggressive 
CRC and important role for MYC-directed transcriptional activation and repression.
Background
The Cancer Genome Atlas (TCGA) project plans to profile genomic changes in 20 different 
cancer types and has published results on two cancer types1,2. We now present results from 
multidimensional analyses of human colorectal cancer (CRC).
CRC is an important contributor to cancer mortality and morbidity. The distinction between 
colon and rectum is largely anatomical, but it impacts both surgical and radiotherapeutic 
management and it may impact prognosis. Most investigators divide CRC biologically into 
those with microsatellite instability (MSI) (located primarily in the right colon and 
frequently associated with the CpG island methylator phenotype (CIMP) and hyper-
mutation) and those that are microsatellite-stable (MSS) but chromosomally unstable (CIN).
A rich history of investigations (for a review see3) has revealed several critical genes and 
pathways important to the initiation and progression of CRC3. These include the WNT, 
RAS-MAPK, PI3K, TGF-β, P53 and DNA mismatch repair pathways. Large-scale 
sequencing analyses4–6 have identified numerous recurrently mutated genes and a recurrent 
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chromosomal translocation. Despite that background, we have not had a fully integrated 
view of the genetic and genomic changes and their significance for colorectal tumorigenesis. 
Further insight into those changes may enable deeper understanding of the pathophysiology 
of CRC and may identify potential therapeutic targets.
Results
Tumor/normal pairs were analyzed by different platforms. The specific numbers of samples 
analyzed by each platform are shown in Supplementary Table 1.
Exome sequence analysis
To define the mutational spectrum, we performed exome capture DNA sequencing on 224 
tumor/normal pairs (Supplementary Table 2 lists all mutations). Sequencing achieved >20X 
coverage of at least 80% of targeted exons. The somatic mutation rates varied considerably 
among the samples. Some had mutation rates <1/106 bases, whereas a few had mutations 
rates >100/106. We separated those cases (84%) with a mutation rate <8.24/106 (median 
number of non-synonymous mutations: 58) and those with mutations rates >12/106 (median 
number of mutations: 728), which we designated as hypermutated (Figure 1).
To assess the basis for the strikingly different mutation rates, we evaluated microsatellite 
instability (MSI)7 and mutations in the DNA mismatch repair pathway8–10 genes MLH1, 
MLH3, MSH2, MSH3, MSH6 and PMS2. Among the 30 hypermutated tumors with a 
complete data set, 23 (77%) had high levels of MSI (MSI-H). Included were 19 with MLH1 
methylation, 17 of which had high CpG island methylation phenotype (CIMP). By 
comparison, the remaining seven hypermutated tumors, including the six with the highest 
mutation rates, lacked MSI-H, CIMP or MLH1 methylation but usually had somatic 
mutations in one or more mismatch repair genes or Polε aberrations rarely seen in the non-
hypermutated tumors (Figure 1).
Gene mutations
Overall, we identified 32 somatic recurrently mutated genes (defined by MutSig11 and 
manual curation) in the hypermutated and non-hypermutated cancers (Figure 1B). After 
removal of non-expressed genes, there were 15 and 17, respectively, in the hypermutated 
and non-hypermutated cancers (Figure 1B, see Supplementary Table 3 for complete list). 
Among the non-hypermutated tumors, the eight most frequently mutated genes were APC, 
TP53, KRAS, PIK3CA, FBXW7, SMAD4, TCF7L2 and NRAS. As expected, the mutated 
KRAS and NRAS genes usually had oncogenic codon 12/13 or 61 mutations, whereas the 
remaining genes had inactivating mutations. CTNNB1, SMAD2, FAM123B and SOX9 were 
also mutated frequently. FAM123B (WTX) is an X-linked negative regulator of WNT 
signaling12, and virtually all its mutations were loss-of-function. Mutations in SOX9, a gene 
important in cell differentiation in the intestinal stem cell niche13,14, have not been 
associated previously with human cancer, but all nine mutated alleles in the non-
hypermutated CRCs were frameshift or nonsense mutations. Tumor suppressors ATM and 
ARID1A also had a disproportionately high number of frameshift or nonsense mutations. 
ARID1A mutations have recently been reported in CRC and many other cancers15,16.
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In the hypermutated tumors, ACVR2A, APC, TGFBR2, MSH3, MSH6, SLC9A9 and 
TCF7L2 were frequent targets of mutation (Figure 1B), along with mostly BRAF V600E 
mutations. However, two genes that were frequently mutated in the non-hypermutated 
cancers were significantly less frequently mutated in hypermutated tumors: TP53 (60 vs 
20%, p < 0.0001), and APC (81% vs 51%, p = 0.0023, both Fisher’s exact test). Other genes, 
including TGFBR2, were recurrently mutated in the hypermutated cancers, but not in the 
non-hypermutated samples. These findings suggest that hypermutated and non-
hypermutated tumors progress through different sequences of genetic events.
As expected, hypermutated tumors with MLH1 silencing and MSI-H exhibited additional 
differences in mutational profile. When we specifically examined 28 genes with long 
mononucleotide repeats in their coding sequences, we found that the rate of frameshift 
mutation was 3.6-fold higher than the rate of such mutation in hypermutated tumors without 
MLH1 silencing, and 50-fold higher than in non-hypermethylated tumors (Supplementary 
Table 2).
Classification of tumors based on mutation rate and methylation pattern
As mentioned above, patients with colon and rectal tumors are managed differently17, and 
epidemiology also shows differences between the two17. An initial integrative analysis of 
MSI status, somatic copy number alterations (SCNAs), CIMP status and gene expression 
profiles of 132 colonic and 62 rectal tumors enabled us to examine possible biological 
differences between tumors in the two locations. Among the non-hypermutated tumors, 
however, the overall patterns of changes in copy number, CIMP, mRNA and miRNA were 
indistinguishable between colon and rectal carcinomas (Figure 2). Based on that result, we 
merged the two for all subsequent analyses.
Unsupervised clustering of the promoter DNA methylation profiles of 236 colorectal tumors 
revealed four subgroups (Supplementary Methods; Supplementary Figure 1). Two of the 
clusters contained tumors with elevated rates of methylation and were classified as CIMP-
high (CIMP-H) and CIMP-low (CIMP-L), as previously described18. The two non-CIMP 
clusters were predominantly from tumors that were non-hypermutated and derived from 
different anatomic locations. mRNA expression profiles separated the colorectal tumors into 
three distinct clusters (Supplementary Figure 2). One significantly overlapped with CIMP-H 
tumors (p=3×10−12) and was enriched with hypermutated tumors; the other two clusters did 
not correspond with any group in the methylation data. Analysis of miRNA expression by 
unsupervised clustering (Supplementary Figure 3) identified no clear distinctions between 
rectal cancers and non-hypermethylated colon cancers.
Chromosomal and sub-chromosomal changes
257 tumors were profiled for somatic copy-number alterations (SCNAs) with Affymetrix 
SNP 6.0 arrays. Of those tumors, 97 were also analyzed by low depth-of-coverage (low-
pass) whole-genome sequencing (WGS). As expected, the hypermutated tumors had far 
fewer SCNAs (Figure 2). No difference was found between MSI and MSS hypermutated 
tumors (Supplementary Figure 4). We used the GISTIC algorithm19 to identify likely gene 
targets of focal alterations. There were several previously well-defined arm-level changes, 
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including gains of 1q, 7p/q, 8p/q, 12q, 13q, 19q, and 20p/q6 (Supplementary Figure 4; 
Supplementary Table 4). Significantly deleted chromosome arms were 18p/q (including 
SMAD4) in 66% of the tumors and 17p/q (including TP53) in 56%. Also significantly 
deleted genes were 1p, 4q, 5q, 8p, 14q, 15q, 20p, and 22q.
We identified 28 recurrent deletion peaks (Supplementary Table 4; Supplementary Figure 
4), including genes like FHIT, A2BP1 and WWOX with large genomic footprints located in 
potentially fragile sites of the genome, in near-diploid hypermutated tumors. Other focal 
deletions involved tumor suppressor genes such as SMAD4, APC, PTEN and SMAD3. A 
significant focal deletion of 10p25.2 spanned four genes, including TCF7L2, which was also 
frequently mutated in our dataset. A gene fusion between adjacent genes VTI1A and 
TCF7L2 through an interstitial deletion was found in 3% of CRCs and is required for 
survival of CRC cells bearing the translocation4.
There were 17 regions of significant focal amplification (Supplementary Table 4). Some of 
them were superimposed on broad gains of chromosome arms. Included were a peak at 
13q12.13 near the peptidase gene USP12 and ~500kB distal to the CRC candidate oncogene 
CDK8; an adjacent peak at 13q12; a peak containing KLF5 at 13q22.1; and a peak at 
20q13.12 adjacent to HNF4A. Peaks on chromosome 8 included 8p12 (which contains the 
histone methyl-transferase WHSC1L1, adjacent to FGFR1) and 8q24 (which contains MYC). 
An amplicon at 17q21.1, found in 4% of the tumors, contains seven genes, including the 
tyrosine kinase ERBB2. ERBB2 amplifications have been described in colon, breast and 
gastric/esophageal tumors, and breast and gastric cancers bearing these amplifications have 
been treated effectively with the anti-ERBB2 antibody trastuzumab20–22.
One of the most common focal amplifications, found in 7% of the tumors, is gain of a 100–
150 kb region of chromosome arm 11p15.5. It contains the genes encoding insulin (INS), 
insulin-like growth factor 2 (IGF2), and tyrosine hydroxylase (TH), as well as miR-483, 
which is embedded within IGF2 (Figure 3a). We found elevated expression of IGF2 and 
miR-483 but not of INS and TH (Figure 3b–c). Immediately adjacent to the amplified region 
is ASCL2, a transcription factor active in specifying intestinal stem cell fate23. Although 
ASCL2 has been implicated as a target of amplification in CRC23–25, it was consistently 
outside the region of amplification and its expression was not correlated with copy-number 
changes. These observations suggest that IGF2 and miR-483 are candidate functional targets 
of 11p15.5 amplification. IGF2 overexpression through loss of imprinting has been 
implicated in the promotion of CRC26,27. MiR-483 may also play a role in CRC 
pathogenesis28.
A subset of tumors (15%) without IGF2 amplification also had dramatically higher levels 
(as much as 100X) of IGF2 gene expression, an effect not attributable to methylation 
changes at the IGF2 promoter. To assess the context of IGF2 amplification/overexpression, 
we systematically looked for mutually exclusive genomic events using the MEMo method29. 
We found a pattern of near exclusivity (corrected p < 0.01) of IGF2 overexpression with 
genomic events known to activate the PI3-K pathway (mutations of PIK3CA/PIK3R1 or 
deletion/mutation of PTEN, Figure 3c, and Supplementary Table 5). The IRS2 gene, whose 
product links IGF1R, the receptor for IGF2, with PI3-K, is on chromosome 13, which is 
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frequently gained in colorectal cancer. Those cases with the highest IRS2 expression were 
mutually exclusive of the cases with IGF2 overexpression (p= 0.04) and also lacked 
mutations in the PI3-K pathway (p= 0.0001)(Figure 3c). Those results strongly suggest that 
the IGF2/IGF1R/IRS2 axis signals to PI3-K in CRC and imply that therapeutic targeting of 
the pathway could act to block PI3-K activity in this subset of patients.
Translocations
To identify novel chromosomal translocations, we performed low-pass, paired-end, whole-
genome sequencing on 97 tumors with matched normals. In each case we achieved sequence 
coverage of ~3–4X and a corresponding physical coverage of 7.5–10X. Despite the low 
genome coverage, we detected 250 candidate inter-chromosomal translocation events (range 
0–10/tumor). Among those events, 212 had one or both breakpoints in an intergenic region, 
whereas the remaining 38 juxtaposed coding regions of two genes in putative fusion events, 
of which 18 were predicted to code for in-frame events (Supplementary Table 6). We found 
three separate cases in which the first two exons of the NAV2 gene on chromosome 11 are 
joined with the 3’ coding portion of TCF7L1 on chromosome 2 (Supplementary Figure 5). 
TCF7L1 encodes TCF3, a member of the TCF/LEF class of transcription factors that 
heterodimerize with nuclear β-catenin to enable β-catenin-mediated transcriptional 
regulation. Intriguingly, in all three cases, the predicted structure of the NAV2-TCF7L1 
fusion protein lacks the TCF3 β-catenin binding domain. This translocation is similar to 
another recurrent translocation identified in CRC, a fusion in which the amino terminus of 
VTI1A is joined to TCF4 that is encoded by TCF7L2, deleted or mutated in 12% of non-
hypermutated tumors and a homolog of TCF7L14. We also observed 21 cases of 
translocation involving TTC28 located on Chromosome 22 (Supplementary Table 6). In all 
cases the fusions predict inactivation of TTC28, which has been identified as a target of p53 
and an inhibitor of tumor cell growth30. Eleven of the 19 (58%) gene-gene translocations are 
validated by either obtaining PCR products and in some case sequencing the junction 
fragments (Supplementary Figure 5).
Altered pathways in CRC
Integrated analysis of mutations, copy-number, and mRNA expression changes in 195 
tumors with complete data enriched our understanding of how some well-defined pathways 
are deregulated. We grouped samples by hypermutation status and identified recurrent 
alterations in the WNT, MAPK, PI3K, TGF-β and p53 pathways (Figure 4, Supplementary 
Figure 6, Supplementary Table 1).
We found that the WNT signaling pathway was altered in 93% of all tumors, including 
biallelic inactivation of APC (Supplementary Table 7) or activating mutations of CTNNB1 in 
~80% of cases. There were also mutations in SOX9 and mutations and deletions in TCF7L2, 
as well as the DKK family members and AXIN2, FBXW7 (Supplementary Figure 7), 
ARID1A and FAM123B/WTX (the latter a negative regulator of WNT/β-catenin signaling12 
found mutated in Wilm’s tumor31). A few mutations in FAM123B/WTX have been described 
in colorectal cancer32. SOX9 has been suggested to play a role in cancer, but no mutations 
have previously been described. The WNT receptor Frizzled (FZD10) was overexpressed in 
~17% of samples, in some instances at levels 100X normal. Altogether, we found 16 
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different altered WNT pathway genes, confirming the importance of that pathway in CRC. 
Interestingly, many of those alterations were found in tumors that harbor APC mutations, 
suggesting that multiple lesions affecting the WNT signaling pathway confer selective 
advantage.
Genetic alterations in the PI3K and RAS-MAPK pathways are common in CRC. In addition 
to IGF2 and IRS2 overexpression, we found mutually exclusive mutations in PIK3R1 and 
PIK3CA as well as deletions in PTEN in 2%, 15% and 4% of non-hypermutated tumors, 
respectively. We found that 55% of non-hypermutated tumors have alterations in KRAS, 
NRAS or BRAF, with a significant pattern of mutual exclusivity (Supplementary Figure 6, 
Supplementary Table 1). We also evaluated mutations in the ERBB family of receptors 
because of the translational relevance of such mutations. Mutations or amplifications in one 
of the four genes are present in 22/165 (13%) non-hypermutated and 16/30 (53%) 
hypermutated cases. Some of the mutations are listed in the COSMIC database33, suggesting 
a functional role. Intriguingly, recurrent V842I ERBB2 and V104M ERBB3 mutations were 
found in four and two non-hypermutated cases, respectively. Mutations and focal 
amplifications of ERBB2 (Supplementary Figure 6) should be evaluated as predictors of 
response to agents that target those receptors. We observed co-occurrence of alterations 
involving the RAS and PI3K pathways in a third of tumors (Figure 4; Fisher’s exact test p = 
0.039). These results suggest that simultaneous inhibition of the RAS and PI3K pathways 
may be required to achieve therapeutic benefit.
The TGF-β signaling pathway is known to be deregulated in colorectal and other cancers34. 
We found genomic alterations in TGFBR1, TGFBR2, ACVR2A, ACVR1B, SMAD2, SMAD3 
and SMAD4 in 27% of the non-hypermutated and 87% of the hypermutated tumors. We also 
evaluated the p53 pathway, finding alterations in TP53 in 59% of non-hypermutated cases 
(mostly biallelic, Supplementary Table 8) and alterations in ATM, a kinase that 
phosphorylates and activates p53 following DNA damage, in 7%. Alterations in those two 
genes showed a trend towards mutual exclusivity (p = 0.016) (Figure 4, Supplementary 
Figure 6, Supplementary Table 1).
We integrated copy number, gene expression, methylation and pathway data using the 
PARADIGM software platform35. The analysis revealed a number of novel characteristics 
of CRC (Figure 5A). For example, despite the diversity in anatomical origin or mutation 
levels, nearly 100% of these tumors have changes in MYC transcriptional targets, both those 
promoted by and those inhibited by MYC. These findings are consistent with patterns 
deduced from genetic alterations (Figure 4) and suggest an important role for MYC in the 
CRC. The analysis also identified several gene networks altered across all tumor samples 
and those with differential alterations in hypermutated vs. non-hypermutated samples 
(Supplementary Table 7, Supplemental Data on the TCGA publication webpage).
Since most of the tumors used in this study were derived from prospective collection, 
survival data are not available. However, the tumors can be classified as aggressive or non-
aggressive on the basis of tumor stage, lymph node status, distant metastasis and vascular 
invasion at the time of surgery. We found numerous molecular signatures associated with 
tumor aggressiveness, a subset of which is shown in Figure 5B. They include specific focal 
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amplifications and deletions, and altered gene expression levels, including those of 
SCN5A36, a reported regulator of colon cancer invasion (full list: Supplementary Tables 10–
11). Association with tumor aggressiveness is also observed in altered expression of 
miRNAs and specific somatic mutations (APC, TP53, PIK3CA, BRAF, and FBXW7; 
Supplementary Figure 8B). Mutations in FBXW7 (38 cases) and distant metastasis (32 
cases) never co-occurred (p = 0.0019). Interestingly, a number of genomic regions have 
multiple molecular associations with tumor aggressiveness that manifest as “clinically-
related genomic hotspots”. Examples of this are the region 20q13.12, which includes a focal 
amplification and multiple genes correlating with tumor aggression, and the region 22q12.3, 
containing APOL637 (Supplementary Figures 8–9).
Discussion
This comprehensive integrative analysis of 224 colorectal tumor/normal pairs provides a 
number of insights into the biology of CRC and identifies potential therapeutic targets. To 
identify possible biological differences in colon and rectum tumors we found, in the non-
hypermutated tumors, irrespective of their anatomical origin, the same type of copy number, 
expression profile, DNA methylation and miRNA changes. Over 94% of them had a 
mutation in one or more members of the WNT signaling pathway, predominantly in APC. 
However, there were some differences between tumors from the right colon and the 
remaining sites. Hypermethylation was more common in the right colon, and three quarters 
of hypermutated samples came from the same site, although not all of them had MSI (Figure 
2). Why most of the hypermutated samples come from the right colon and why there are two 
classes of tumors at this site is not known. The origins of the colon from embryonic midgut 
and hindgut may provide an explanation. Since the survival of patients with high MSI 
cancers are better and these cancers have hypermutation, mutation rate may be a better 
prognostic indicator.
Whole exome sequencing and integrative analysis of genomic data provided further insights 
into the pathways that are dysregulated in CRC. We found that 93% of non-hypermutated 
and 97% of hypermutated cases had deregulated WNT signaling pathway. Novel findings 
included recurrent mutations in FAM123B, ARID1A and SOX9 and very high levels of 
overexpression of the WNT ligand receptor Frizzled 10. To our knowledge, SOX9 has not 
previously been described as frequently mutated in any human cancer. SOX9 is 
transcriptionally repressed by WNT signaling, and the SOX9 protein has been shown to 
facilitate β-catenin degradation38. ARID1A is frequently mutated in gynecological cancers 
and has been shown to suppress Myc transcription39. Activation of WNT signaling and 
inactivation of the TGF-β signaling pathway are known to result in activation of MYC. Our 
mutational and integrative analyses emphasize the critical role of MYC in CRC. We also 
compared our results with other large-scale analyses6 and find many similarities and few 
differences in mutated genes (Supplementary Table 3).
Our integrated analysis revealed a diverse set of changes in TCF/LEF encoding genes 
suggesting additional roles for TCF/LEF factors in CRC beyond being passive partners for 
β-catenin.
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Our data suggest a number of therapeutic approaches to CRC. Included are WNT signaling 
inhibitors and small-molecule β-catenin inhibitors that are showing initial promise40–42. We 
find that several proteins in the RTK/RAS and PI3K pathways including IGF2, IGFR, 
ERBB2, ERBB3, MEK, AKT and mTOR could be targets for inhibition.
Our analyses show that non-hypermutated adenocarcinomas of the colon and rectum are not 
distinguishable at the genomic level. However, tumors from the right/ascending colon were 
more likely to be hypermethylated and to have elevated mutation rates than were other 
CRCs. As has been recognized previously, activation of the WNT signaling pathway and 
inactivation of the TGF-β signaling pathway, resulting in increased activity of MYC, are 
nearly ubiquitous events in CRC. Genomic aberrations frequently target the MAPK and PI3-
K pathways but less frequently target receptor tyrosine kinases. In conclusion, the data 
presented here provide an unprecedented resource for understanding this deadly disease and 
identifying possibilities for treating it in a targeted way.
Methods Summary
Tumor and normal samples were processed by either of two Biospecimen Core Resources 
(BCRs), and aliquots of purified nucleic acids were shipped to the genome characterization 
and sequencing centers (Supplementary Methods). The BCRs provided sample sets in 
several different batches. To assess any batch effects we examined the mRNA expression, 
miRNA expression and DNA methylation data sets using a combination of cluster analysis, 
enhanced principal component analysis, and analysis of variance (Supplementary Methods). 
Although some differences among batches were detected, we did not correct them 
computationally because the differences were generally modest and because some of them 
may reflect biological phenomena (Supplementary Methods).
We used Affymetrix SNP 6.0 microarrays to detect copy-number alterations. A subset of 
samples was subjected to low pass (2–5X) whole genome sequencing (Illumina HiSeq), in 
part for detection of SCNA and chromosomal translocations43,44. Gene expression profiles 
were generated using Agilent microarrays and RNA-Seq. DNA methylation data were 
obtained using Illumina Infinium (HumanMethylation27) arrays. DNA sequencing of coding 
regions was performed by exome capture followed by sequencing on the SOLiD or Illumina 
HiSeq platforms. Details of the analytical methods used are described in Supplementary 
Methods.
All of the primary sequence files are deposited in dbGap and all other data are deposited at 
the Data Coordinating Center (DCC) for public access (http://cancergenome.nih.gov/). Data 
matrices and supporting data can be found at http://tcga-data.nci.nih.gov/docs/publications/
coadread_2012/. The data can also be explored via the ISB Regulome Explorer (http://
explorer.cancerregulome.org/) and the cBio Cancer Genomics Portal (http://cbioportal.org). 
Descriptions of the data can be found at https://wiki.nci.nih.gov/x/j5dXAg and in 
Supplementary Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mutation frequencies in human CRC
A. Mutation frequencies in each of the tumors. Note a clear separation of hypermutated and 
non-hypermutated samples. Inset: Mutations in mismatch repair genes and POLE among 
the hypermutated samples. The order of the samples is the same as in Figure 1A. B. 
Significantly mutated genes in non-hypermutated and hypermutated tumors. Blue bars 
represent genes identified by MutSig and genes in black bars are identified by manual 
examination of sequence data.
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Figure 2. Integrative analysis of genomic changes in 195 CRC tumors
Hypermutated tumors have near diploid genomes and are highly enriched for 
hypermethylation, CIMP expression phenotype, and BRAF V600E mutations. Non-
hypermutated tumors originating from different sites are virtually indistinguishable from 
each other based on their copy-number alteration patterns, DNA methylation, or gene 
expression patterns. Copy-number changes of the 22 autosomes are shown in shades of red 
for copy-number gains and shades of blue for copy-number losses.
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Figure 3. Copy number changes and structural aberrations in CRC
A. Focal amplification of 11p15.5. Segmented DNA copy-number data from SNP arrays and 
low pass whole genome sequencing are shown. Each row represents a patient; amplified 
regions are shown in red. B. Correlation of expression levels with copy number changes for 
IGF2 and miR-483. C. IGF2 amplification and over-expression are mutually exclusive of 
alterations in PI3K signaling genes. D. Recurrent NAV2-TCF7L2 fusions. The structure of 
the two genes, locations of the breakpoints leading to the translocation and circular 
representations of all rearrangements in tumors with a fusion are shown. The red line lines 
represent the NAV2-TCF7L2 fusions, black lines indicate other rearrangements. The inner 
ring represents copy-number changes (blue = loss, pink = gain).
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Figure 4. Diversity and frequency of genetic changes leading to deregulation of signaling 
pathways in CRC
Non-hypermuated (n = 165) and hypermutated (n = 30) samples with complete data were 
analyzed separately. Alterations are defined by somatic mutations, homozygous deletions, 
high-level, focal amplifications, and, in some cases, by significant up- or down-regulation of 
gene expression (IGF2, FZD10, SMAD4). Alteration frequencies are expressed as a 
percentage of all cases; activated genes are red and inactivated genes are blue. The bottom 
panel shows for each sample if at least one gene in each of the five pathways is altered.
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Figure 5. Integrative analyses of multiple data sets
A. Clustering of genes and pathways affected in colon and rectum tumors deduced by 
PARADIGM analysis. Blue = under-expressed relative to normal and red = overexpressed 
relative to normal. Some of the pathways deduced by this method are shown on the right. B. 
Gene expression signatures and SCNAs associated with tumor aggression. Molecular 
signatures (rows) that show statistically significant association with tumor aggressiveness 
according to selected clinical assays (columns) are displayed in color, with red indicating 
markers of tumor aggressiveness, and blue the markers of less aggressive tumors. 
Significance is based on the combined p-value from the weighted Fisher’s method, corrected 
for multiple testing. Color intensity and score is in accordance with the strength of an 
individual clinical-molecular association, and is proportional to log10(p), where p is p-value 
for that association. To limit the vertical extent of the figure, gene expression signatures are 
restricted to combined p-value p<10−9, SCNAs to p<10−7 and features are shown only if 
they are also significant in the subset of non-MSI-H samples (the analysis was performed 
separately on the full data as well as on the MSI-H and non-MSI-H subgroups).
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